EMA Authorised: Omjjara (Momelotinib dihydrochloride monohydrate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The European Medicines Agency authorized Omjjara (momelotinib dihydrochloride monohydrate) for myeloproliferative disorders including myelofibrosis with splenom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Disorders
• Splenomegaly

Drugs mentioned

• Omjjara (momelotinib dihydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Splenomegaly;Myeloproliferative Disorders. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 27/03/2025. Orphan medicine